Display options
Cite
Paschou SA, Papadopoulou-Marketou N, Chrousos GP, et al. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2017;7(1):R38-R46doi: 10.1530/EC-17-0347.
Paschou, S. A., Papadopoulou-Marketou, N., Chrousos, G. P., & Kanaka-Gantenbein, C. (2018). On type 1 diabetes mellitus pathogenesis. Endocrine connections, 7(1), R38-R46. https://doi.org/10.1530/EC-17-0347
Paschou, Stavroula A, et al. "On type 1 diabetes mellitus pathogenesis." Endocrine connections vol. 7,1 (2018): R38-R46. doi: https://doi.org/10.1530/EC-17-0347
Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2018 Jan;7(1):R38-R46. doi: 10.1530/EC-17-0347. Epub 2017 Nov 30. PMID: 29191919; PMCID: PMC5776665.
Copy Download .nbib Format: NLM
Share it on

Endocr Connect. 2018 Jan;7(1):R38-R46. doi: 10.1530/EC-17-0347. Epub 2017 Nov 30.

On type 1 diabetes mellitus pathogenesis.

Endocrine connections

Stavroula A Paschou, Nektaria Papadopoulou-Marketou, George P Chrousos, Christina Kanaka-Gantenbein

Affiliations

  1. Division of EndocrinologyMetabolism and Diabetes, First Department of Pediatrics, 'Aghia Sophia' Children's Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  2. Division of EndocrinologyMetabolism and Diabetes, First Department of Pediatrics, 'Aghia Sophia' Children's Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece [email protected].

PMID: 29191919 PMCID: PMC5776665 DOI: 10.1530/EC-17-0347

Abstract

Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of β cells of the endocrine pancreas. Pathogenesis of T1DM is different from that of type 2 diabetes mellitus, where both insulin resistance and reduced secretion of insulin by the β cells play a synergistic role. We will present genetic, environmental and immunologic factors that destroy β cells of the endocrine pancreas and lead to insulin deficiency. The process of autoimmune destruction takes place in genetically susceptible individuals under the triggering effect of one or more environmental factors and usually progresses over a period of many months to years, during which period patients are asymptomatic and euglycemic, but positive for relevant autoantibodies. Symptomatic hyperglycemia and frank diabetes occur after a long latency period, which reflects the large percentage of β cells that need to be destroyed before overt diabetes become evident.

© 2018 The authors.

Keywords: autoimmunity; genetics; microbiota; pathogenesis; type 1 diabetes

References

  1. Diabetes. 1994 Jan;43(1):87-94 - PubMed
  2. Diabetes. 2004 Nov;53(11):3020-3 - PubMed
  3. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E681-8 - PubMed
  4. Diabetes. 1998 Apr;47(4):566-9 - PubMed
  5. Mol Genet Metab. 2004 Mar;81(3):187-95 - PubMed
  6. Nature. 2005 May 12;435(7039):220-3 - PubMed
  7. Rev Endocr Metab Disord. 2017 Sep;18(3):335-346 - PubMed
  8. J Virol. 2012 Oct;86(20):11151-62 - PubMed
  9. Nutrients. 2013 Sep 12;5(9):3551-62 - PubMed
  10. Diabetes. 2012 Nov;61(11):2763-75 - PubMed
  11. Genes (Basel). 2017 Feb 16;8(2): - PubMed
  12. PLoS One. 2010 Sep 09;5(9):null - PubMed
  13. PLoS One. 2014 Jun 11;9(6):e99646 - PubMed
  14. Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14074-9 - PubMed
  15. Diabetologia. 2014 May;57(5):902-8 - PubMed
  16. BMJ. 1999 Mar 13;318(7185):698-702 - PubMed
  17. J Pediatr Endocrinol Metab. 2016 Apr;29(4):395-400 - PubMed
  18. Diabetes. 1996 Jul;45(7):926-33 - PubMed
  19. Diabetologia. 2014 Jul;57(7):1500-1 - PubMed
  20. JAMA. 2003 Oct 1;290(13):1713-20 - PubMed
  21. Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5 - PubMed
  22. JAMA. 2007 Sep 26;298(12):1420-8 - PubMed
  23. Mol Cell Endocrinol. 2016 Jan 5;419:83-91 - PubMed
  24. Diabetologia. 2013 Sep;56(9):1888-97 - PubMed
  25. Curr Diab Rep. 2012 Oct;12(5):456-62 - PubMed
  26. Neuron. 2004 Dec 16;44(6):977-86 - PubMed
  27. Nat Rev Endocrinol. 2010 May;6(5):279-89 - PubMed
  28. Diabetes. 2012 May;61(5):1192-8 - PubMed
  29. Hum Immunol. 2001 Apr;62(4):299-309 - PubMed
  30. Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5115-20 - PubMed
  31. Diabetes. 2007 Sep;56(9):2405-9 - PubMed
  32. Diabetologia. 1993 Aug;36(8):687-95 - PubMed
  33. Lancet. 1978 Jan 14;1(8055):57-60 - PubMed
  34. Diabetologia. 1994 Apr;37(4):381-7 - PubMed
  35. Diabetes. 1995 Jun;44(6):608-13 - PubMed
  36. Pharmacol Res. 2015 Aug;98:9-15 - PubMed
  37. Rev Med Virol. 2010 Sep;20(5):265-80 - PubMed
  38. Diabetes. 1996 Apr;45(4):513-21 - PubMed
  39. Nat Rev Endocrinol. 2009 Apr;5(4):219-26 - PubMed
  40. Diabetes. 2017 Dec;66(12 ):3122-3129 - PubMed
  41. Diabetes. 2005 Mar;54(3):906-8 - PubMed
  42. N Engl J Med. 2004 Apr 1;350(14):1398-404 - PubMed
  43. Diabetes. 2011 Dec;60(12 ):3300-6 - PubMed
  44. Nature. 1990 Sep 13;347(6289):151-6 - PubMed
  45. Diabetes. 2017 Jan;66(1):100-112 - PubMed
  46. Curr Opin Genet Dev. 2007 Jun;17(3):193-200 - PubMed
  47. J Clin Endocrinol Metab. 2010 Oct;95(10):4712-9 - PubMed
  48. N Engl J Med. 1979 May 24;300(21):1173-9 - PubMed
  49. N Engl J Med. 1994 Nov 24;331(21):1428-36 - PubMed
  50. J Clin Invest. 2006 Dec;116(12):3258-65 - PubMed
  51. Diabetes Res Clin Pract. 2000 Mar;47(3):199-207 - PubMed
  52. Nat Med. 1998 Jul;4(7):781-5 - PubMed
  53. Clin Exp Immunol. 2012 Apr;168(1):39-46 - PubMed
  54. J Clin Invest. 1990 Apr;85(4):1315-9 - PubMed
  55. Diabetes. 1997 Jan;46(1):143-9 - PubMed
  56. Diabetologia. 1997 May;40(5):550-6 - PubMed
  57. Diabetes Metab Res Rev. 2013 Nov;29(8):646-54 - PubMed
  58. Curr Opin Infect Dis. 2013 Jun;26(3):263-9 - PubMed
  59. Science. 2009 Apr 17;324(5925):387-9 - PubMed
  60. N Engl J Med. 2004 May 13;350(20):2068-79 - PubMed
  61. Am J Epidemiol. 2005 Jul 1;162(1):3-16 - PubMed
  62. J Autoimmun. 2005 Dec;25(4):312-8 - PubMed
  63. J Autoimmun. 2005;25 Suppl:56-62 - PubMed
  64. Nat Genet. 1998 Jul;19(3):297-300 - PubMed
  65. Nat Genet. 2014 Aug;46(8):812-814 - PubMed
  66. Diabetes. 2004 Jul;53(7):1884-9 - PubMed

Publication Types